Equities research analysts predict that Clovis Oncology (NASDAQ:CLVS) will post ($1.73) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Clovis Oncology’s earnings, with the lowest EPS estimate coming in at ($1.84) and the highest estimate coming in at ($1.57). Clovis Oncology posted earnings per share of ($1.27) in the same quarter last year, which would suggest a negative year-over-year growth rate of 36.2%. The company is expected to report its next earnings report on Monday, February 25th.
According to Zacks, analysts expect that Clovis Oncology will report full year earnings of ($6.77) per share for the current fiscal year, with EPS estimates ranging from ($7.02) to ($6.50). For the next financial year, analysts forecast that the business will report earnings of ($5.47) per share, with EPS estimates ranging from ($6.93) to ($4.27). Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for Clovis Oncology.
Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.11). The business had revenue of $22.76 million for the quarter, compared to analyst estimates of $30.11 million. Clovis Oncology had a negative return on equity of 108.92% and a negative net margin of 390.65%. The business’s revenue was up 35.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.24) earnings per share.
Several equities analysts have weighed in on the stock. Leerink Swann upgraded shares of Clovis Oncology from a “market perform” rating to an “outperform” rating in a report on Tuesday. Barclays decreased their target price on shares of Clovis Oncology from $58.00 to $40.00 and set an “overweight” rating on the stock in a report on Wednesday, October 31st. Piper Jaffray Companies decreased their target price on shares of Clovis Oncology to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, October 31st. SunTrust Banks lowered shares of Clovis Oncology to a “buy” rating and boosted their target price for the company from $20.00 to $70.00 in a report on Wednesday, October 31st. Finally, Oppenheimer reiterated a “hold” rating on shares of Clovis Oncology in a report on Tuesday, October 30th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company’s stock. Clovis Oncology has an average rating of “Hold” and a consensus price target of $56.32.
Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Clovis Oncology by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,445,064 shares of the biopharmaceutical company’s stock valued at $130,551,000 after purchasing an additional 104,655 shares during the last quarter. Macquarie Group Ltd. boosted its holdings in shares of Clovis Oncology by 27.1% in the 3rd quarter. Macquarie Group Ltd. now owns 878,530 shares of the biopharmaceutical company’s stock valued at $25,802,000 after buying an additional 187,071 shares in the last quarter. Sector Gamma AS boosted its holdings in shares of Clovis Oncology by 6.7% in the 3rd quarter. Sector Gamma AS now owns 185,577 shares of the biopharmaceutical company’s stock valued at $5,450,000 after buying an additional 11,685 shares in the last quarter. MetLife Investment Advisors LLC boosted its holdings in shares of Clovis Oncology by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 34,083 shares of the biopharmaceutical company’s stock valued at $1,001,000 after buying an additional 12,116 shares in the last quarter. Finally, Opus Point Partners Management LLC boosted its holdings in shares of Clovis Oncology by 534.1% in the 3rd quarter. Opus Point Partners Management LLC now owns 82,430 shares of the biopharmaceutical company’s stock valued at $2,421,000 after buying an additional 69,430 shares in the last quarter.
CLVS traded up $0.91 on Wednesday, reaching $19.99. 11,355,554 shares of the company’s stock were exchanged, compared to its average volume of 1,769,300. The firm has a market capitalization of $907.17 million, a PE ratio of -3.90 and a beta of 2.12. Clovis Oncology has a twelve month low of $11.50 and a twelve month high of $69.02. The company has a current ratio of 9.03, a quick ratio of 8.46 and a debt-to-equity ratio of 2.46.
Clovis Oncology Company Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Further Reading: What are the components of an earnings report?
Get a free copy of the Zacks research report on Clovis Oncology (CLVS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.